TabletsClinical Overview
Pazopanib Tablets (200mg, 400mg) is an oral second-generation multi-tyrosine kinase inhibitor on the WHO Model List framework. It potently inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, and c-KIT, starving tumors of blood supply. Indicated for advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 800 mg once daily on an EMPTY STOMACH: at least 1 hour before or 2 hours after food with a full glass of water. Swallow tablets whole; do NOT crush or chew, as crushing increases bioavailability and escalates systemic toxicity.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypertension, diarrhea, hair color depigmentation (hair lightening), nausea, anorexia, vomiting, fatigue, elevated transaminases. Rare/Severe: Severe fatal hepatotoxicity, arterial thromboembolic events, gastrointestinal perforation, and QT prolongation / Torsades de Pointes.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Severe, fatal hepatotoxicity; monitor serum liver tests every 2 weeks for the first 9 weeks, then monthly. Must be taken on an empty stomach. Discontinue if baseline transaminases rise significantly or bilirubin exceeds 2× ULN.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.